**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 85938

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Serum vascular endothelial growth factor and cortisol expression to predict prognosis of patients with hypertensive cerebral hemorrhage**

Zhang CY *et al.* Hypertensive hemorrhage prognosis: VEGF-cortisol study

Chao-Yong Zhang, Bin Wang, Xiang-Ting Hua, Kui Fan, Yu-Feng Li

**Chao-Yong Zhang, Xiang-Ting Hua, Kui Fan, Yu-Feng Li,** Department of Neurosurgery, Taihe Hospital Affiliated to Wannan Medical College, Taihe County People’s Hospital, Fuyang 236600, Anhui Province, China

**Bin Wang,** Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei 230000, Anhui Province, China

**Author contributions:** Zhang CY and Wang B contributed equally to this work; Zhang CY, Wang B, Hua XT, Fan K, and Li YF, designed the research study; Zhang CY, Wang B, Hua XT, and Fan K performed the research; Zhang CY, Wang B, and Li YF analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

**Corresponding author: Bin Wang, Doctor, Chief Doctor,** Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei 230000, Anhui Province, China. hulier888@163.com

**Received:** June 6, 2023

**Revised:** June 26, 2023

**Accepted:** July 14, 2023

**Published online:** August 16, 2023

**Abstract**

BACKGROUND

Cerebral hemorrhage is a common and severe complication of hypertension in middle-aged and elderly men.

AIM

To investigate the correlation between vascular endothelial growth factor (VEGF) and cortisol (Cor) and the prognosis of patients with hypertensive cerebral hemorrhage.

METHODS

A hundred patients with hypertensive intracerebral hemorrhage were enrolled from January 2020 to December 2022 and assigned to the hypertensive intracerebral hemorrhage group. Another 100 healthy people who were examined at our hospital during the same period were selected and assigned to the healthy group. Peripheral venous blood was collected, and serum Cor and VGEF levels were measured through enzyme linked immunosorbent assay.

RESULTS

A statistically significant difference in serum Cor and VGEF levels was observed among patients with varying degrees of neurological impairment (*P* < 0.05). Serum Cor and VGEF levels were significantly higher in the severe group than in the mild-to-moderate group. Cor and VEGF levels were significantly higher in patients with poor prognoses than in those with good prognoses. Multiple logistic regression analysis revealed that serum Cor and VGEF levels were independent factors affecting hypertensive intracerebral hemorrhage (*P* < 0.05).

CONCLUSION

Cor and VGEF are associated with the occurrence and development of hypertensive cerebral hemorrhage and are significantly associated with neurological impairment and prognosis of patients.

**Key Words:** Hypertension; Cerebral hemorrhage; Vascular endothelial growth factor; Cortisol; Prognosis; Treatment

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang CY, Wang B, Hua XT, Fan K, Li YF. Serum vascular endothelial growth factor and cortisol expression to predict prognosis of patients with hypertensive cerebral hemorrhage. *World J Clin Cases* 2023; 11(23): 5455-5461

**URL:** <https://www.wjgnet.com/2307-8960/full/v11/i23/5455.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v11.i23.5455

**Core Tip:** Investigation of the correlation between vascular endothelial growth factor (VEGF) and cortisol (Cor) levels and the prognosis of patients with hypertensive intracerebral hemorrhage indicated that Cor and VEGF are associated with the occurrence and development of cerebral hemorrhage, as well as neurological impairment and patient prognosis. Thus, Cor and VEGF may act as potential biomarkers for predicting the prognosis of patients with hypertensive intracerebral hemorrhage.

**INTRODUCTION**

Cerebral hemorrhage is a common and severe complication of hypertension in middle-aged and elderly men[1-3]. This complication usually occurs in hypertensive patients who are emotionally disturbed or overworked. It is characterized by rapid onset, rapid progression, poor prognosis, and high mortality and is a severe health risk. Brain hemorrhage is associated with risk factors such as age, smoking, and alcohol abuse; however, its exact pathogenesis remains unclear and effective treatment is lacking.

Vascular endothelial growth factor (VEGF) is a cytokine that specifically enhances vascular permeability, promotes neovascularization and participates in neuroprotection and other biological functions[4-9]. The relationship between VEGF and hypertensive cerebral hemorrhage has recently become a hot research topic. In addition, cortisol (Cor) is a sensitive indicator of stress in vivo[10-14]. VEGF and Cor play a crucial role in secondary brain injury in patients with cerebral hemorrhage[15-20]; however, the relationship of VEGF and Cor with the prognosis of hypertensive cerebral hemorrhage has rarely been reported. Moreover, the effect of VEGF and Cor on serological parameters in patients with hypertensive cerebral hemorrhage remains unclear. We here investigated the usefulness of serum VEGF and Cor expression in predicting the prognosis of patients with hypertensive cerebral hemorrhage[21-23].

**MATERIALS AND METHODS**

***General information***

One hundred patients with the hypertensive cerebral hemorrhage who were admitted to our hospital from January 2020 to December 2022 were selected and assigned to the hypertensive cerebral hemorrhage group. Another 100 healthy people who were examined at our hospital during the same period were selected as the healthy group. Patients with first-onset hypertensive cerebral hemorrhage in whom the diagnosis was confirmed through head magnetic resonance or computed tomography imaging and who were ≥ 60 years of age were included in the study. Patients with traumatic cerebrovascular disease; occult cerebrovascular malformation; cerebral hemorrhage; transient ischemic attack; cardiogenic cerebral embolism; recent history of major surgery; head trauma injuries; organic lesions of the liver, heart, and kidney; vasodilation; volume expansion and thrombolytic therapy before blood collection; severe infections; malignant tumors; immune system diseases; hematological diseases; and cardiovascular diseases were excluded. The healthy group included 51 men and 49 women having a mean age of 69.40 ± 3.19 years and a body mass index of 59.99 ± 7.08 kg/m2. The cerebral hemorrhage group included 52 men and 33 women having a mean age of 69.47 ± 3.26 years and a body mass index of 60.00 ± 7.04 g/m2. The differences between the groups were not statistically significant (*P* > 0.05) and were comparable. Patients in the cerebral hemorrhage group were divided into three subgroups, severe (*n* = 33), moderate (*n* = 34), and mild (*n* = 33), according to their degree of disease[24-28]. Patients in the cerebral hemorrhage group were divided into the vulnerable plaque subgroup (*n* = 50) and the stable plaque subgroup (*n* = 50) based on the nature of the carotid atherosclerotic plaque. The study was approved by the ethics committee of the hospital. All study participants signed the informed consent form.

***Treatment methods***

The hypertensive cerebral hemorrhage group was provided basic symptomatic treatment upon admission, including thrombolysis, oxygenation, anticoagulation, cerebral nerve nutrition, cerebral edema relief, maintenance of acid-base balance, anti-platelet aggregation, and blood glucose and blood pressure control.

***Observation indicators***

First, 3–5 mL of fasting elbow venous blood is collected from all participants, left to stand for 60 min at room temperature, and centrifuged at 3000 r/min for 10 min. The supernatant was stored in a refrigerator at −80℃. Serum VEGF and Cor levels were measured using enzyme linked immunosorbent assay (ELISA) by strictly following the instructions of the ELISA kit (Shanghai Qiao Yu Biotechnology Co., Ltd.).

***Statistical methods***

SPSS 22.0 statistical software was used for data processing and analysis. The measured data were expressed as mean ± SD deviation, and a t-test was used for comparison between groups.

**RESULTS**

***Comparison of the serum VEGF and Cor levels between the healthy and cerebral hemorrhage groups***

The levels of serum VEGF and Cor in the cerebral hemorrhage group were significantly higher than those in the healthy group, and the differences were statistically significant (all *P* < 0.05, Table 1).

***Comparison of the serum VEGF and Cor levels in patients with different degrees of injury in the brain hemorrhage group***

There were significant differences in the serum VEGF and Cor levels among patients with different degrees of injury (all *P* < 0.05). The levels of serum VEGF and Cor in the severe group were significantly higher than those in the mild and moderate groups, and the levels of serum VEGF and Cor in the moderate group were significantly higher than those in the mild group (all *P* < 0.05, Table 2).

***Comparison of the serum VEGF and Cor levels in patients with different prognosis levels in the cerebral hemorrhage group***

The levels of serum VEGF and Cor in patients with poor prognosis were significantly higher than those in patients with good prognosis (all *P* < 0.05, Table 3).

***Multi-factor logistic regression analysis of patient prognosis***

Multivariate logistic regression analysis was performed using the prognosis level of patients with hypertensive cerebral hemorrhage as the dependent variable and serum VEGF and Cor as the independent variables. The results showed that serum VEGF and Cor were independent influencing factors of hypertensive cerebral hemorrhage (all *P* < 0.05, Table 4).

**DISCUSSION**

Cerebral hemorrhage is among the severe complications of hypertension that mainly occurs in middle-aged and elderly populations[29-32]. It is characterized by the rapid onset and progression of the disease, which can lead to sequelae such as hemiplegia, cognitive impairment, and cerebral hernia, thus bringing a heavy burden to families and society[33-35]. To formulate reasonable treatment plans and improve patients’ living standards, rapidly and accurately assessing the prognosis of hypertensive intracerebral hemorrhage is crucial. With the rapid development of molecular biology, the role of various active factors in the development of hypertensive intracerebral hemorrhage has recently attracted considerable attention[36-38]. VEGF is a homologous dimer glycoprotein. It is a specific mitogen that directly acts on vascular endothelial cells. VEGF mainly increases vascular permeability, promotes vascular regeneration, and participates in neuroprotection[39,40]. The study results revealed that the VEGF expression level was statistically and significantly higher in patients with cerebral hemorrhage than in the control group (*P* < 0.05). As the main stressor, hypertensive intracerebral hemorrhage can rapidly activate the hypothalamus pituitary adrenal axis, upregulate adrenal function, and increase the Cor levels. The present results indicated that the serum levels of VEGF and Cor in the observation group were higher than those in the control group, implying that VEGF and Cor may be involved in the occurrence of acute cerebral hemorrhage. Past studies have shown that, when compared with the healthy controls, the serum VEGF and Cor levels in patients with acute cerebral hemorrhage were significantly increased, while the serum VEGF and Cor levels were positively correlated with the American Institutes of Health Stroke Scale scores. The present results also suggested that, with the aggravation of neurological deficits in patients with acute cerebral hemorrhage, the serum VEGF and Cor levels gradually increased. This could be because an increase or decrease of the VEGF and Cor levels can promote the enhancement of inflammatory response.

However, this study still has certain limitations. Firstly, we only analyzed regional research data, and information were obtained from a single hospital, which may lead to biased results. In the future, data from different countries, regions, and age groups should be analyzed to eliminate contingency and address the aforementioned limitations. In addition, follow-up studies should enrol a larger sample size and increase the scope of oral education to cover subjects such as educational forms and educational models.

**CONCLUSION**

The study results thus revealed that serum Cor and VEGF levels were significantly higher in the study group than in the control group. These levels increased with the degree of nerve injury, thus indicating that serum Cor and VEGF mediate the occurrence and development of hypertensive cerebral hemorrhage. Moreover, serum Cor and VEGF levels may be related to the prognosis of hypertensive intracerebral hemorrhage.

**ARTICLE HIGHLIGHTS**

***Research background***

Cerebral hemorrhage is a common and serious complication of hypertension affecting middle-aged and elderly men. General anesthesia can easily induce complications such as cognitive dysfunction in such patients, which is not conducive to postoperative recovery.

***Research motivation***

To investigate the correlation between vascular endothelial growth factor(VEGF) and cortisol (Cor) and the prognosis of patients with hypertensive cerebral hemorrhage.

***Research objectives***

To provide a reference for the prognosis and anesthesia of clinically related operations.

***Research methods***

Randomized controlled method and double-blinded method.

***Research results***

Cor and VGEF levels were statistically and significantly higher in patients with poor prognosis than in those with good prognosis (*P* < 0.05). Multifactor logistic regression analysis revealed that serum Cor and VGEF levels were independent factors influencing hypertensive cerebral hemorrhage.

***Research conclusions***

Cor and VGEF are associated with the occurrence and development of hypertensive cerebral hemorrhage and are significantly associated with neurological impairment and prognosis of patients.

***Research perspectives***

Future studies could focus on exploring the potential mechanisms underlying the correlation between serum Cor and VEGF levels and hypertensive intracerebral hemorrhage. Additionally, more clinical studies are needed to validate the potential of serum Cor and VEGF as biomarkers for predicting patient prognosis and guiding clinical treatment decisions. Finally, further research could aim to investigate potential therapeutic strategies targeting Cor and VEGF to improve patient outcomes.

**REFERENCES**

1 **Abboud T**, Mende KC, Jung R, Czorlich P, Vettorazzi E, Priefler M, Kluge S, Westphal M, Regelsberger J. Prognostic Value of Early S100 Calcium Binding Protein B and Neuron-Specific Enolase in Patients with Poor-Grade Aneurysmal Subarachnoid Hemorrhage: A Pilot Study. *World Neurosurg* 2017; **108**: 669-675 [PMID: 28943424 DOI: 10.1016/j.wneu.2017.09.074]

2 **Gómez-Touriño I**, Simón-Vázquez R, Alonso-Lorenzo J, Arif S, Calviño-Sampedro C, González-Fernández Á, Pena-González E, Rodríguez J, Viñuela-Roldán J, Verdaguer J, Cordero OJ, Peakman M, Varela-Calvino R. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes. *Clin Exp Immunol* 2015; **180**: 207-217 [PMID: 25516468 DOI: 10.1111/cei.12572]

3 **Xu Z**, Han K, Chen J, Wang C, Dong Y, Yu M, Bai R, Huang C, Hou L. Vascular endothelial growth factor is neuroprotective against ischemic brain injury by inhibiting scavenger receptor A expression on microglia. *J Neurochem* 2017; **142**: 700-709 [PMID: 28632969 DOI: 10.1111/jnc.14108]

4 **Liu M**, Wu Y, Liu Y, Chen Z, He S, Zhang H, Wu L, Tu F, Zhao Y, Liu C, Chen X. Basic Fibroblast Growth Factor Protects Astrocytes Against Ischemia/Reperfusion Injury by Upregulating the Caveolin-1/VEGF Signaling Pathway. *J Mol Neurosci* 2018; **64**: 211-223 [PMID: 29299743 DOI: 10.1007/s12031-017-1023-9]

5 **Zhao C**, Sun G, Li S, Lang MF, Yang S, Li W, Shi Y. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. *Proc Natl Acad Sci U S A* 2010; **107**: 1876-1881 [PMID: 20133835 DOI: 10.1073/pnas.0908750107]

6 **Pandey AK**, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. *Hypertension* 2018; **71**: e1-e8 [PMID: 29279311 DOI: 10.1161/HYPERTENSIONAHA.117.10271]

7 **Matsuo R**, Ago T, Kamouchi M, Kuroda J, Kuwashiro T, Hata J, Sugimori H, Fukuda K, Gotoh S, Makihara N, Fukuhara M, Awano H, Isomura T, Suzuki K, Yasaka M, Okada Y, Kiyohara Y, Kitazono T. Clinical significance of plasma VEGF value in ischemic stroke - research for biomarkers in ischemic stroke (REBIOS) study. *BMC Neurol* 2013; **13**: 32 [PMID: 23566234 DOI: 10.1186/1471-2377-13-32]

8 **Rensma SP**, van Sloten TT, Launer LJ, Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. *Neurosci Biobehav Rev* 2018; **90**: 164-173 [PMID: 29656031 DOI: 10.1016/j.neubiorev.2018.04.003]

9 **Blair GW**, Hernandez MV, Thrippleton MJ, Doubal FN, Wardlaw JM. Advanced Neuroimaging of Cerebral Small Vessel Disease. *Curr Treat Options Cardiovasc Med* 2017; **19**: 56 [PMID: 28620783 DOI: 10.1007/s11936-017-0555-1]

10 **Xu S**, Du B, Shan A, Shi F, Wang J, Xie M. The risk factors for the postoperative pulmonary infection in patients with hypertensive cerebral hemorrhage: A retrospective analysis. *Medicine (Baltimore)* 2020; **99**: e23544 [PMID: 33371078 DOI: 10.1097/MD.0000000000023544]

11 **Hori YS**, Ohkura T, Ebisudani Y, Umakoshi M, Ishi M, Oda K, Aoi M, Inoue T, Furujo M, Tanaka H, Fukuhara T. Hypertensive Cerebral Hemorrhage in a Patient with Turner Syndrome Caused by Deletion in the Short Arm of the X Chromosome. *Pediatr Neurosurg* 2018; **53**: 167-170 [PMID: 29275412 DOI: 10.1159/000485252]

12 **Hu S**, Ma Q, Li B, Wu Q, Han R. Association of Hypothyroidism with Hypertensive Intracerebral Hemorrhage: A Case-Control Study. *World Neurosurg* 2020; **134**: e8-e11 [PMID: 31421295 DOI: 10.1016/j.wneu.2019.08.041]

13 **Tang Y**, Yin F, Fu D, Gao X, Lv Z, Li X. Efficacy and safety of minimal invasive surgery treatment in hypertensive intracerebral hemorrhage: a systematic review and meta-analysis. *BMC Neurol* 2018; **18**: 136 [PMID: 30176811 DOI: 10.1186/s12883-018-1138-9]

14 **Zhang S**, Zhang X, Ling Y, Li A. Predicting Recurrent Hypertensive Intracerebral Hemorrhage: Derivation and Validation of a Risk-Scoring Model Based on Clinical Characteristics. *World Neurosurg* 2019; **127**: e162-e171 [PMID: 30876994 DOI: 10.1016/j.wneu.2019.03.024]

15 **Lo BWY**, Teitelbaum JS. Hyperthermia, cerebral edema, and outcome in intracerebral hemorrhage: Too darn hot. *Neurology* 2020; **94**: 687-688 [PMID: 32221029 DOI: 10.1212/WNL.0000000000009284]

16 **You S**, Zheng D, Delcourt C, Sato S, Cao Y, Zhang S, Yang J, Wang X, Lindley RI, Robinson T, Anderson CS, Chalmers J. Determinants of Early Versus Delayed Neurological Deterioration in Intracerebral Hemorrhage. *Stroke* 2019; **50**: 1409-1414 [PMID: 31136288 DOI: 10.1161/STROKEAHA.118.024403]

17 **Li H**, Xu H, Wen H, Liu T, Sun Y, Xiao N, Bai C, Ge J, Wang X, Song L, Song Y, Zhang Y, Chen J. Overexpression of LH3 reduces the incidence of hypertensive intracerebral hemorrhage in mice. *J Cereb Blood Flow Metab* 2019; **39**: 547-561 [PMID: 30516406 DOI: 10.1177/0271678X18815791]

18 **Tsai HH**, Lee BC, Huang CY, Tsai LK, Tang SC, Jeng JS, Chen YF. Asymptomatic Striatocapsular slit-like Hemorrhage as a Severity Marker in Patients with Hypertensive Angiopathy. *J Stroke Cerebrovasc Dis* 2020; **29**: 105153 [PMID: 32912549 DOI: 10.1016/j.jstrokecerebrovasdis.2020.105153]

19 **Han M**, Ding S, Zhang Y, Lin Z, Li K. Serum Copper Homeostasis in Hypertensive Intracerebral Hemorrhage and its Clinical Significance. *Biol Trace Elem Res* 2018; **185**: 56-62 [PMID: 29322430 DOI: 10.1007/s12011-017-1227-4]

20 **Gavito-Higuera J**, Khatri R, Qureshi IA, Maud A, Rodriguez GJ. Aggressive blood pressure treatment of hypertensive intracerebral hemorrhage may lead to global cerebral hypoperfusion: Case report and imaging perspective. *World J Radiol* 2017; **9**: 448-453 [PMID: 29354210 DOI: 10.4329/wjr.v9.i12.448]

21 **Xia L**, Han Q, Ni XY, Chen B, Yang X, Chen Q, Cheng GL, Liu CF. Different Techniques of Minimally Invasive Craniopuncture for the Treatment of Hypertensive Intracerebral Hemorrhage. *World Neurosurg* 2019; **126**: e888-e894 [PMID: 30872203 DOI: 10.1016/j.wneu.2019.03.006]

22 **Guo XJ**, Ding WL, Zhu HH. Clinical efficacy and prognosis of aspirin combined with clopidogrel in patients with cerebral hemorrhage after operation. *Eur Rev Med Pharmacol Sci* 2020; **24**: 4056 [PMID: 32374003 DOI: 10.26355/eurrev\_202004\_20971]

23 **Shao X**, Wang Q, Shen J, Liu J, Chen S, Jiang X. Comparative Study of Micro-Bone Window and Conventional Bone Window Microsurgery for Hypertensive Intracerebral Hemorrhage. *J Craniofac Surg* 2020; **31**: 1030-1033 [PMID: 32118662 DOI: 10.1097/SCS.0000000000006259]

24 **Mao J**, Jiang W, Liu G, Jiang B. Serum calcium levels at admission is associated with the outcomes in patients with hypertensive intracerebral hemorrhage. *Br J Neurosurg* 2019; **33**: 145-148 [PMID: 30775930 DOI: 10.1080/02688697.2019.1571162]

25 **Rivera-Lara L**, Murthy SB, Nekoovaght-Tak S, Ali H, McBee N, Dlugash R, Ram M, Thompson R, Awad IA, Hanley DF, Ziai WC; CLEAR Investigators. Influence of Bleeding Pattern on Ischemic Lesions After Spontaneous Hypertensive Intracerebral Hemorrhage with Intraventricular Hemorrhage. *Neurocrit Care* 2018; **29**: 180-188 [PMID: 29589328 DOI: 10.1007/s12028-018-0516-x]

26 **Wang T**, Zhao QJ, Gu JW, Shi TJ, Yuan X, Wang J, Cui SJ. Neurosurgery medical robot Remebot for the treatment of 17 patients with hypertensive intracerebral hemorrhage. *Int J Med Robot* 2019; **15**: e2024 [PMID: 31267676 DOI: 10.1002/rcs.2024]

27 **Sun S**, Li Y, Zhang H, Gao H, Zhou X, Xu Y, Yan K, Wang X. Neuroendoscopic Surgery *vs* Craniotomy for Supratentorial Hypertensive Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. *World Neurosurg* 2020; **134**: 477-488 [PMID: 31669683 DOI: 10.1016/j.wneu.2019.10.115]

28 **Song GF**, Li X, Feng Y, Yu CH, Lian XY. Acupuncture combined Bobath approach for limbs paralysis after hypertensive intracerebral hemorrhage: A protocol for a systematic review. *Medicine (Baltimore)* 2019; **98**: e14750 [PMID: 30855470 DOI: 10.1097/MD.0000000000014750]

29 **Ziai WC**, Thompson CB, Mayo S, McBee N, Freeman WD, Dlugash R, Ullman N, Hao Y, Lane K, Awad I, Hanley DF; Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III) Investigators. Intracranial Hypertension and Cerebral Perfusion Pressure Insults in Adult Hypertensive Intraventricular Hemorrhage: Occurrence and Associations With Outcome. *Crit Care Med* 2019; **47**: 1125-1134 [PMID: 31162192 DOI: 10.1097/CCM.0000000000003848]

30 **Tarantini S**, Valcarcel-Ares NM, Yabluchanskiy A, Springo Z, Fulop GA, Ashpole N, Gautam T, Giles CB, Wren JD, Sonntag WE, Csiszar A, Ungvari Z. Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. *Aging Cell* 2017; **16**: 469-479 [PMID: 28295976 DOI: 10.1111/acel.12583]

31 **Esnafoglu E**, Ayyıldız SN, Cırrık S, Erturk EY, Erdil A, Daglı A, Noyan T. Evaluation of serum Neuron-specific enolase, S100B, myelin basic protein and glial fibrilliary acidic protein as brain specific proteins in children with autism spectrum disorder. *Int J Dev Neurosci* 2017; **61**: 86-91 [PMID: 28711670 DOI: 10.1016/j.ijdevneu.2017.06.011]

32 **Matz O**, Arndt A, Litmathe J, Dafotakis M, Block F. [Risk factors for hypertensive and cerebral amyloid angiopathy associated intracerebral hemorrhage: a retrospective comparison]. *Fortschr Neurol Psychiatr* 2018; **86**: 763-769 [PMID: 30419583 DOI: 10.1055/a-0732-5523]

33 **Eskioglou E**, Huchmandzadeh Millotte M, Amiguet M, Michel P. National Institutes of Health Stroke Scale Zero Strokes. *Stroke* 2018; **49**: 3057-3059 [PMID: 30571424 DOI: 10.1161/STROKEAHA.118.022517]

34 **Ruilian L**, Honglin Q, Jun X, Jianxin L, Qingyun B, Yilin C, Haifeng M. H(2)S-mediated aerobic exercise antagonizes the hippocampal inflammatory response in CUMS-depressed mice. *J Affect Disord* 2021; **283**: 410-419 [PMID: 33581467 DOI: 10.1016/j.jad.2021.02.005]

35 **Hagag AA**, El Frargy MS, Yonis RL, Al-Ashmawy GM. Diagnostic Value of Assessment of Serum Cortisol, Hepcidin and Thyroid Hormones Levels in Neonates with Late-Onset Sepsis. *Infect Disord Drug Targets* 2021; **21**: 248-256 [PMID: 32216741 DOI: 10.2174/1871526520666200327185244]

36 **Feng Y**, Feng Q, Lv Y, Song X, Qu H, Chen Y. The relationship between iron metabolism, stress hormones, and insulin resistance in gestational diabetes mellitus. *Nutr Diabetes* 2020; **10**: 17 [PMID: 32513913 DOI: 10.1038/s41387-020-0122-9]

37 **Georgantzi K**, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. *Pediatr Hematol Oncol* 2018; **35**: 156-165 [PMID: 29737901 DOI: 10.1080/08880018.2018.1464087]

38 **Wang Y**, Xu S, Pan S, Ouyang H, Zang Z, Tan J. Association of serum neuron-specific enolase and bilirubin levels with cerebral dysfunction and prognosis in large-artery atherosclerotic strokes. *J Cell Biochem* 2018; **119**: 9685-9693 [PMID: 30191604 DOI: 10.1002/jcb.27281]

39 **Mozafari J**, Motamed H, Masoumi K, Hanafi MG, Fahimi MA, Derakhshani Z, Ehyaie F. Characteristics of S100B and Neuron Specific Enolase in Differentiating Acute Vertigo Cases with Central Cause; a Diagnostic Accuracy Study. *Arch Acad Emerg Med* 2020; **8**: e3 [PMID: 32021984]

40 **Jung YJ**, Lee JS, Shin WC. Surface electromyography analysis of contralateral lower extremity tremor following thalamic hemorrhage. *Neurol Sci* 2015; **36**: 1281-1283 [PMID: 25502345 DOI: 10.1007/s10072-014-2023-y]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Taihe Hospital Affiliated to Wannan Medical College Institutional Review Board.

**Informed consent statement:** This study has signed an informed consent form with the patient.

**Conflict-of-interest statement:** All authors have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 6, 2023

**First decision:** June 21, 2023

**Article in press:** July 14, 2023

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Dechsling A, Norway; Frazier TW, United States **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Cai YX

**Table 1 Comparison of the serum vascular endothelial growth factor and cortisol levels between the healthy and cerebral hemorrhage groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | ***n*** | **VEGF (pg/L)** | **Cor (nmol/L)** |
| Cerebral hemorrhage group | 100 | 1.43 ± 0.52 | 796.61 ± 50.23 |
| Healthy group | 100 | 1.01 ± 0.34 | 499.42 ± 47.11 |
| *t* value |  | 12.374 | 27.142 |
| *P* value |  | 0.000 | 0.000 |

VEGF: Vascular endothelial growth factor; Cor: Cortisol.

**Table 2 Comparison of the serum vascular endothelial growth factor and cortisol levels in patients with different degrees of injury in the brain hemorrhage group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Degree of damage** | ***n*** | **VEGF (pg/L)** | **Cor (nmol/L)** |
| Mild | 33 | 1.13 ± 0.78 | 547.33 ± 40.19 |
| Moderate | 34 | 1.50 ± 0.59a | 746.34 ± 46.22a |
| Severe | 33 | 1.66 ± 0.64a,b | 998.42 ± 35.36a,b |
| *t* value |  | 9.278 | 19.741 |
| *P* value |  | 0.012 | 0.000 |

a*P* < 0.05 when compared to patients with a mild injury.

b*P* < 0.05 compared to patients with a moderate injury. VEGF: Vascular endothelial growth factor; Cor: Cortisol.

**Table 3 Comparison of the serum vascular endothelial growth factor and cortisol levels in patients with different prognosis levels in the cerebral hemorrhage group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Prognosis level** | ***n*** | **VEGF (pg/L)** | **Cor (nmol/L)** |
| Good | 61 | 1.21 ± 0.69 | 661.75 ± 35.42 |
| Difference | 39 | 1.58 ± 0.71 | 899.31 ± 36.78 |
| *t* value |  | 15.617 | 24.874 |
| *P* value |  | 0.000 | 0.000 |

VEGF: Vascular endothelial growth factor; Cor: Cortisol.

**Table 4 Multi-factor logistic regression analysis of patient prognosis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Influencing factors** | **B** | **SX** | **WaldX2** | ***P* value** | **OR (95% CI)** |
| VEGF | 1.526 | 0.025 | 22.623 | 0.000 | 2.985 (1.261-5.328) |
| Cor | 1.102 | 0.024 | 16.375 | 0.000 | 2.036 (0.857-2.235) |

OR: Odds ratio; CI: Confidence interval; VEGF: Vascular endothelial growth factor; Cor: Cortisol.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**